In March 2023 Gynoveda’s chief executive told the press the company was running at a ₹100 crore (about $10.4 million; $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) annual revenue rate, three years after launch. Its audited books tell a slower story: operating revenue of ₹67.2 crore in FY24 and ₹68.1 crore in FY25, with the net loss widening to ₹10.5 crore in FY25.
That gap between a run-rate headline and a flat annual filing is the whole Gynoveda story in miniature. The brand built a genuinely new category, selling Ayurvedic tablet programs for period disorders and fertility direct to Indian women, raised roughly $11 million, put Taapsee Pannu on its packaging, and then ran into the two walls that catch most direct-to-consumer health brands at once: profitability and regulation. In September 2024 a state drug regulator raided a Gynoveda warehouse over its advertising claims.
Quick facts
| Company | Gynoveda Femtech Private Limited (CIN U21002MH2019PTC327679; incorporated 5 July 2019, Mumbai) — as per Tracxn/RoC |
| Founded | 2019 |
| Founder(s) | Vishal Gupta (CEO), Rachana Gupta, Dr. Aarati Patil |
| Businesses | Ayurvedic direct-to-consumer women’s health — tablet programs for PCOS/PCOD, irregular and painful periods, fertility and menopause; sold via own site, marketplaces and clinics |
| Latest FY revenue | ₹68.1 crore (FY25) — reported by Inc42 |
| Latest FY profit/loss | Net loss of ₹10.5 crore (FY25) — reported by Inc42 |
| Listed | Private (not listed) |
| Last valuation | Not publicly disclosed; total funding about $11 million across three rounds (Inc42/Tracxn) |
| Key shareholders / CEO | CEO Vishal Gupta; backers include India Alternatives Fund, Fireside Ventures, Wipro Enterprises, RPG Ventures, Dharampal Satyapal (DS Group) and Alteria Capital |
What Gynoveda does
Gynoveda sells Ayurvedic self-care programs for women’s reproductive and menstrual health, direct to consumers. Its formulations, marketed under names such as MYRAA and VAMAA, are pitched as treating the root cause of period disorders rather than masking symptoms. The core buyer is a woman between roughly 15 and 55 dealing with PCOS/PCOD, irregular or heavy periods, period pain, or difficulty conceiving, who wants an alternative to hormonal medication. A short online self-assessment (“period test”) routes her to a personalised tablet blend, backed by a doctor consult and a large online community the company calls its “Circle of Sisterhood.”
The founding insight
Gynoveda began with a couple, not a lab. Vishal and Rachana Gupta were classmates at St. Thomas High School in Mumbai and had been together for about three decades before they started the company in their forties, leaving corporate careers — Vishal in strategy, operations and finance, Rachana in marketing and consumer insight. The insight they kept returning to was structural: between the ages of 15 and 55 a woman goes through close to 400 menstrual cycles plus pregnancy and menopause, yet the health system treats each as an isolated episode. They saw a gap between how often women deal with reproductive-health problems and how little continuous, non-judgemental care exists for them.
The couple seeded the idea with roughly $2 million of their own savings (company-stated) and brought in Dr. Aarati Patil, a doctor with a postgraduate qualification in Ayurvedic obstetrics and gynaecology, to build formulations grounded in classical texts such as the Charak Samhita. The bet was that Ayurveda, packaged as a modern, evidence-cued consumer brand rather than a dusty prescription, could win women who had cycled through conventional options without relief.
The struggle years
Gynoveda has never reported an annual profit, and the pattern of its losses is the honest measure of how hard the category is.
- FY21: operating revenue of ₹5.40 crore against a net loss of ₹2.28 crore (Entrackr, from MCA filings).
- FY22: revenue grew 3.25x to ₹17.58 crore, but the loss also widened to ₹4.51 crore (Entrackr, MCA filings) — growth bought with spend.
- FY25: revenue essentially flat at ₹68.1 crore versus ₹67.2 crore in FY24, while the net loss more than tripled to ₹10.5 crore and total expenses rose to ₹78.6 crore (Inc42).
The sharpest setback was not financial. On 13 September 2024 the Maharashtra Food and Drug Administration raided a Gynoveda warehouse in Bhiwandi, seizing medicines worth ₹6.08 lakh and restricting distribution of stock valued at about ₹3.62 crore pending labelling compliance. The regulator alleged violations of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, flagging packaging claims that touched conditions such as hypertension and diabetes, and missing batch and expiry details on some bottles (The Bridge Chronicle, September 2024).
The turning point
The single event that changed Gynoveda’s trajectory was its Series A. On 14 March 2023 the company raised $10 million (about ₹96 crore) led by India Alternatives Fund. Put the numbers on either side of that date and the shape is clear: the company entered the round with FY22 operating revenue of ₹17.58 crore, and by FY24 it was reporting ₹67.2 crore — close to a fourfold increase over two years. The capital paid for R&D, new formulations, distribution and brand-building, including signing Taapsee Pannu as ambassador in 2022. It also raised the bar: the same round that funded the growth is the one against which the later revenue plateau, and the widening FY25 loss, now read as a stall.
The money behind it
Gynoveda’s funding is modest by femtech standards and heavily front-loaded into one round.
- Founders’ capital: about $2 million from personal savings at the start (company-stated).
- Seed: about $1 million, led by Fireside Ventures, October 2019 (Entrackr, Femtech Insider).
- Series A: $10 million (about ₹96 crore), 14 March 2023, led by India Alternatives Fund, with Wipro Enterprises, RPG Ventures, Dharampal Satyapal (DS Group) and venture-debt firm Alteria Capital, plus a follow-on from Fireside Ventures (Entrackr, Entrepreneur India).
- Total raised: about $11 million across three rounds; Tracxn logs roughly $10.9 million from about 10 investors.
- Valuation: not publicly disclosed for any round.
What each backer changed is worth naming: Fireside Ventures, a consumer-brand specialist, gave early validation; India Alternatives anchored the growth round; Wipro Enterprises and DS Group brought strategic FMCG heft; and Alteria’s venture debt let the company add capital without diluting further. There has been no publicly reported new equity round since March 2023.
How it makes money
Gynoveda earns almost entirely from selling branded Ayurvedic tablet programs, and the economics hinge on how long a customer stays on treatment.
- Money in: multi-month tablet programs (a one-month PCOS pack is two bottles of 240 tablets), with recommended courses of 6 to 12 months depending on severity — a subscription-like, repeat-purchase model rather than one-off sales.
- Channels: its own site and shop, plus marketplaces including Amazon, PharmEasy and HyugaLife; the company also markets a clinic network and doctor consults.
- Funnel: a free online “period test” and content-and-community engine (the “Circle of Sisterhood”) acquire and qualify buyers before a personalised blend is recommended.
- Where margin sits: branded Ayurvedic SKUs carry healthy gross margins, but the model is marketing-heavy. In FY25 total expenses of ₹78.6 crore exceeded revenue of ₹68.1 crore, so the operating result was a loss (Inc42).
- The part people get wrong: this is not a quick impulse purchase. Revenue quality depends on adherence over months, so retention and repeat orders — not first-time conversion — decide whether the unit economics work.
The numbers
Figures below are operating revenue and net loss in ₹ crore, from MCA/RoC filings as reported by Entrackr (FY21, FY22) and Inc42 (FY24, FY25). FY23 is not shown as an audited annual figure here; the widely quoted “₹100 crore” for that period was a company-stated revenue run rate (Mint, March 2023), not an audited full-year number.
| Fiscal year | Operating revenue (₹ crore) | Net loss (₹ crore) |
| FY21 | 5.40 | 2.28 |
| FY22 | 17.58 | 4.51 |
| FY24 | 67.2 | 3.1 |
| FY25 | 68.1 | 10.5 |
The story the table tells: explosive early growth (roughly 3.25x from FY21 to FY22) gave way to a plateau, with FY25 revenue up only about 1.5% over FY24 even as the loss more than tripled. Growth got expensive faster than it got profitable.
Where the money comes from
Gynoveda does not publish a formal segment or geography breakdown, so the split below is directional, drawn from company statements and product data rather than audited segment reporting.
- By condition: PCOS/PCOD, irregular and painful periods dominate the catalogue, with fertility and menopause as adjacent lines; the company has said more than 400,000 women have used its PCOS program (company-stated).
- By geography: overwhelmingly domestic. As of the 2023 raise the company cited about 300,000 women served across roughly 20,000 Indian pincodes; international expansion has been discussed since 2021 but is not a disclosed revenue driver.
- By channel: a mix of its own D2C storefront and third-party marketplaces (Amazon, PharmEasy, HyugaLife), supplemented by clinics — the exact channel share is not public.
- The surprise: the value is not in the first bottle. Because courses run 6 to 12 months, the customers who matter most are repeat buyers on long programs, which makes adherence and community engagement the real revenue engine.
The risks
- Advertising and regulatory risk (already realised): Ayurvedic products that make disease claims run straight into the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, ASCI guidelines, and ad-platform policies that reject cure claims for PCOS, thyroid, infertility and the like. The September 2024 FDA raid, the ₹6.08 lakh seizure and the ₹3.62 crore distribution hold show this is a live, not theoretical, exposure.
- Evidence and trust: the brand’s “treats the root cause” positioning outruns the large-scale, peer-reviewed clinical evidence typical of drug claims. That leaves it vulnerable to skeptical coverage, negative reviews and refunds, all of which raise the cost of acquiring and keeping customers.
- Unit economics and funding: flat FY25 revenue, a loss that more than tripled to ₹10.5 crore, expenses above revenue, only about $11 million raised in total, and no new equity round since March 2023 together point to pressure on cash runway and dependence on paid marketing that is getting harder to run under ad-platform health rules.
The takeaway
Gynoveda’s lesson is that in regulated health categories, the claim is the product — and it is also the liability. The same bold, root-cause messaging that let a two-founder Ayurveda brand carve out a new femtech niche and quadruple revenue in two years is what drew a regulator’s raid and what ad platforms increasingly refuse to carry. A brand can win the category and still be boxed in by how it is allowed to talk about what it sells. For any founder building in health, wellness or supplements, the durable moat is not the loudest promise; it is the evidence and the compliance that let you keep making the promise at all.
Frequently asked questions
Who founded Gynoveda and when?
Gynoveda was founded in 2019 by Vishal Gupta (CEO) and Rachana Gupta, a married couple who had been together for about 30 years, along with Dr. Aarati Patil, a doctor with a postgraduate qualification in Ayurvedic obstetrics and gynaecology. The legal entity is Gynoveda Femtech Private Limited, incorporated in Mumbai on 5 July 2019.
Was Gynoveda on Shark Tank India?
We could not find any verifiable record that Gynoveda appeared on or received a deal from Shark Tank India, across the show’s season records and reputable coverage. Its known institutional funding came through a seed round and a $10 million Series A in March 2023, not a televised pitch. We have left the claim out rather than assert something we could not confirm.
How much money has Gynoveda raised?
About $11 million in total across three rounds. That includes a roughly $1 million seed led by Fireside Ventures in 2019 and a $10 million Series A in March 2023 led by India Alternatives Fund, with Wipro Enterprises, RPG Ventures, DS Group and Alteria Capital participating. No valuation has been publicly disclosed.
Is Gynoveda profitable?
No. It has reported losses every year for which filings are available, and in FY25 the net loss widened to ₹10.5 crore on revenue of ₹68.1 crore, with total expenses of ₹78.6 crore (Inc42).
What happened with the FDA raid?
On 13 September 2024 the Maharashtra Food and Drug Administration raided a Gynoveda warehouse in Bhiwandi, seized medicines worth ₹6.08 lakh, and restricted distribution of about ₹3.62 crore of stock pending labelling compliance, alleging violations of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 over its packaging claims (The Bridge Chronicle, September 2024).
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Inc42 — Gynoveda financials and company profile (FY24, FY25 revenue and loss), 2026
- Entrackr — “Ayurveda D2C startup Gynoveda raises $10 Mn in a Series A round” (FY21, FY22 revenue and loss; seed round), March 2023
- Entrepreneur India — “Gynoveda Raises $10 Million In Series A Funding Round” (investors, use of funds), March 2023
- Femtech Insider — “Indian DTC Startup Gynoveda Raises $10M in Series A Funding” (founders, investors, run rate), March 2023
- Mint (via X/@livemint) — Vishal Gupta on ₹100 crore revenue run rate FY20–FY23, March 2023
- Tracxn — Gynoveda Femtech Private Limited (CIN, incorporation date, total funding), 2026
- The Bridge Chronicle — “FDA Raids Gynoveda Warehouse in Bhiwandi, Seizes Medicines Worth ₹6 Lakh,” September 2024
- YourStory / HerStory — “Femtech startup Gynoveda goes beyond Tier I cities” (origin, reach), September 2021
- Gynoveda official site and shop — product programs, MYRAA/VAMAA, customer counts (company-stated), 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.
